This trial is active, not recruiting.

Condition narcolepsy
Treatment orexine a
Sponsor Zentrum für Integrative Psychiatrie
Start date June 2007
End date August 2009
Trial identifier NCT00484757, DFG-SFB654/C5-Narkorex, Narkorex


15 patients with narcolepsy and 15 healthy controls will be included in the study. According to a randomized, double-blind protocol they will receive intranasally at night first Orexine A and approximately two weeks later placebo or vice versa. Thereafter sleep will be recorded, the cytokine-system and neurocognition characterized.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model crossover assignment
Masking double-blind
Primary purpose basic science

Primary Outcomes

Effect of orexine A on sleep, neurocognition and immune-system
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Narcolepsy - Age >18 - Informed consent - GERMAN fluently spoken Exclusion Criteria: - Additional severe psychiatric or somatic disorders - Pregnancy or nursing - Anemia (Hb<10g/dl)

Additional Information

Principal investigator Dunja Hinze-Selch, MD
Trial information was received from ClinicalTrials.gov and was last updated in April 2009.
Information provided to ClinicalTrials.gov by Zentrum für Integrative Psychiatrie.